ADMA Biologics (NASDAQ:ADMA) Rating Increased to Moderate Buy at Raymond James Financial

ADMA Biologics (NASDAQ:ADMA) was upgraded by analysts at Raymond James Financial to a “moderate buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other research firms have also recently commented on ADMA. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Zacks Research lowered shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 26th. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Canaccord Genuity Group lowered their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Finally, Mizuho lowered their price target on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $19.67.

ADMA Biologics Stock Up 4.4%

ADMA stock opened at $8.48 on Wednesday. The company has a 50-day moving average of $9.21 and a two-hundred day moving average of $14.26. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of 12.47 and a beta of 0.72. The company has a debt-to-equity ratio of 0.51, a current ratio of 6.95 and a quick ratio of 3.93. ADMA Biologics has a 52-week low of $7.21 and a 52-week high of $22.37.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.19. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. The business had revenue of $114.49 million during the quarter, compared to analyst estimates of $139.98 million. During the same quarter last year, the business posted $0.11 earnings per share. ADMA Biologics’s revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities research analysts anticipate that ADMA Biologics will post 0.84 EPS for the current year.

Insider Buying and Selling at ADMA Biologics

In other news, Director Jerrold B. Grossman purchased 12,500 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $8.01 per share, with a total value of $100,125.00. Following the acquisition, the director owned 513,884 shares in the company, valued at approximately $4,116,210.84. The trade was a 2.49% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Several large investors have recently modified their holdings of ADMA. Westfield Capital Management Co. LP bought a new position in ADMA Biologics during the third quarter worth $74,866,000. Janus Henderson Group PLC boosted its stake in ADMA Biologics by 3,906.1% during the fourth quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock worth $71,820,000 after acquiring an additional 3,838,158 shares in the last quarter. Capital Research Global Investors boosted its stake in ADMA Biologics by 104.0% during the fourth quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock worth $121,067,000 after acquiring an additional 3,383,559 shares in the last quarter. Caligan Partners LP bought a new position in ADMA Biologics during the third quarter worth $38,653,000. Finally, UBS Group AG lifted its stake in shares of ADMA Biologics by 129.9% in the fourth quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock valued at $83,345,000 after buying an additional 2,581,670 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.